

# RECEIVED

APR 10 2002

TECH CENTER 1600/2900



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE



Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/023,975
		Filing Date	12/17/2001
		First Named Inventor	Christiane YOAKIM
		Group Art Unit	1644 1626
		Examiner Name	
Sheet 1 of 2	Attorney Docket Number	13/073	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
KS		SHAH, ET AL; "Papillomaviruses", Fields Virology, 3d ed, Ch. 66, 2077-2109, 1996	
KS		BEUTNER, ET AL; "Therapeutic Approaches to Genital Warts"; Am. J. Med., 1997, 102(5A), 28-37	
KS		HUGHES, ET AL; "E1 Protein of Human Papillomavirus is a DNA Helicase/ATPase"; Nucleic Acids Res., 1993, Vol. 21, No. 25, 5817-5823	
KS		KUO, ET AL; "Cell-free Replication of the Human Papillomavirus DNA with Homologous Viral E1 and E2 Proteins and Human Cell Extracts", J. Biol. Chem., 1994, Vol 269, No. 39, 24058-24065	
KS		SEO, ET AL; "Bovine papilloma virus (BPV)-encoded E1 protein contains multiple activities required for BPV DNA replication"; Proc. natl. Acad. Sci USA; 1993; Vol. 90, 702-706	
KS		YANG, ET AL; "The E1 protein of bovine papilloma virus 1 is an ATP-dependent DNA helicase"; Proc. Natl. Acad. Sci. USA; 1993; Vol. 90, 5086-5090	
KS		MacPHERSON, ET AL; "The Bovine Papilloma Virus E1 Protein Has ATPase Activity Essential to Viral DNA Replication and Efficient Transformation in Cells"; Virology, 1994, 204, 403-408	
KS		MOHR, ET AL; "Targeting the E1 Replication Protein to the Papillomavirus Origin of Replication by Complex Formation with the E2 Transactivator"; Science, 1990, 250; 1694-1699	
KS		SEO, ET AL; "Bovine papilloma virus (BPV)-encoded E2 protein enhances binding of E1 protein to the BPV replication origin"; Proc. Natl. Acad. Sci. USA, 1993; Vol. 90, 2865-2869	
KS		LIU, ET AL; "The Functions of Human Papillomavirus Type 11 E1, E2, and E2C Proteins in Cell-free DNA Replication"; J. Biol. Chem., 1995, 270(45), 27283-27291	
KS		BUCKLE, ET AL; "Antiallergic Activity of 2-Nitroindan-1,3-diones"; J. Med. Chem., 1973, Vol. 16, No. 12, 1334-1339	

Examiner Signature	Kamal Saeed	Date Considered	06/03/03
--------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



RECEIVED

APR 10 2002

TECH. REV. 10/29/2001

Approved for use through 10/29/2001 by U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	10/023,975
		Filing Date	12/17/2001
		First Named Inventor	Christiane YOAKIM
		Group Art Unit	1644 1125
		Examiner Name	
Sheet 2 of 2	Attorney Docket Number	13/073	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KS		KOSKINEN, ET AL; "Diazo Transfer Reactions under Mildly Basic Conditions"; J. Chem. Soc. Chem. Commun.; 1990, 652-653	
KS		VILLENEUVE, ET AL; "A Rapid, Mild and Acid-Free Procedure for the Preparation of Acyl Chlorides Including Formyl Chloride"; Tetrahedron Letters, 1997, Vol. 38, No. 37, 6489-6492	
KS		KRYSIN, ET AL; "1,3-Dipolar Cycloaddition of 2-Benzylideneindan-3-Dione-alpha-Oxide to Olefins"; Khimiya Geterotsiklicheskikh Soedinenii, 1987, 11, 1463-1466	✓
KS		REDDY, ET AL; "Lewis Acid and Hexamethyldisilazane-Promoted Efficient Synthesis of N-Alkyl- and N-Arylimide Derivatives"; J. Org. Chem. 1997, 62, 2652-2654	
KS		CHIANG, ET AL; "Viral E1 and E2 proteins support replication of homologous and heterologous papillomaviral origins"; Proc. Natl. Acad. Sci. USA, 1992, Vol. 89, 5799-5803	
KS		McKAY; "Binding of a Simian Virus 40 T Antigen-related Protein to DNA"; J. Mol. Biol. 1981, 145, 471-488	

Examiner Signature	kamal saeed	Date Considered	06/03/02
--------------------	-------------	-----------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.